Immuneering Corp (NASDAQ:IMRX) — Market Cap & Net Worth
Market Cap & Net Worth: Immuneering Corp (IMRX)
Immuneering Corp (NASDAQ:IMRX) has a market capitalization of $324.14 Million ($324.14 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14646 globally and #3294 in its home market, demonstrating a -12.40% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Immuneering Corp's stock price $5.37 by its total outstanding shares 64569967 (64.57 Million). Analyse Immuneering Corp cash conversion from operations to see how efficiently the company converts income to cash.
Immuneering Corp Market Cap History: 2021 to 2026
Immuneering Corp's market capitalization history from 2021 to 2026. Data shows change from $1.04 Billion to $346.74 Million (-22.08% CAGR).
Index Memberships
Immuneering Corp is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.01% | #393 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1400 of 3165 |
Weight: Immuneering Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Immuneering Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Immuneering Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1043053.31x
Immuneering Corp's market cap is 1043053.31 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.04 Billion | $2.08 Million | -$33.54 Million | 501.98x | N/A |
| 2022 | $313.16 Million | $316.95K | -$50.51 Million | 988.05x | N/A |
| 2023 | $474.59 Million | $455.00 | -$53.47 Million | 1043053.31x | N/A |
Competitor Companies of IMRX by Market Capitalization
Companies near Immuneering Corp in the global market cap rankings as of May 4, 2026.
Key companies related to Immuneering Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Immuneering Corp Historical Marketcap From 2021 to 2026
Between 2021 and today, Immuneering Corp's market cap moved from $1.04 Billion to $ 346.74 Million, with a yearly change of -22.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $346.74 Million | -18.39% |
| 2025 | $424.87 Million | +199.09% |
| 2024 | $142.05 Million | -70.07% |
| 2023 | $474.59 Million | +51.55% |
| 2022 | $313.16 Million | -70.01% |
| 2021 | $1.04 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Immuneering Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $324.14 Million USD |
| MoneyControl | $324.14 Million USD |
| MarketWatch | $324.14 Million USD |
| marketcap.company | $324.14 Million USD |
| Reuters | $324.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Immuneering Corp
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 … Read more